Skip to main content

Find Clinical Trials

Home
Conditions
Lipodystrophy, Familial Partial

Clinical trial condition

Lipodystrophy, Familial Partial

Explore clinical trials studying Lipodystrophy, Familial Partial. Study availability and eligibility vary by location and protocol.

15 public trials 4 recruiting studies

Refine in advanced search Browse all conditions

Lipodystrophy, Familial Partial trial results

Completed

Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)

NCT03514420

Conditions: Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Diabetes Mellitus, Diabetes Mellitus, Lipoatrophic, +16 more
Locations: Clinical Site Ann Arbor, Michigan, United States

View Trial Details

Completed

CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy

NCT02654977

Conditions: Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Familial Partial Lipodystrophy, +16 more
Locations: University of Michigan Ann Arbor, Michigan, United States

View Trial Details

Completed

Study of Gemcabene in Adults With FPLD

NCT03508687

Conditions: Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Dyslipidemias, +18 more
Locations: University of Michigan Ann Arbor, Michigan, United States

View Trial Details

Completed

Lipodystrophy Connect Patient Registry

NCT02577952

Conditions: Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Laminopathies, +12 more
Locations: PatientCrossroads San Francisco, California, United States

View Trial Details

Active, Not Recruiting

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

NCT06548100

Conditions: Body Weight, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Diabetes Mellitus, +28 more
Locations: National Institutes of Health Bethesda, Maryland, United States

University of Michigan Ann Arbor, Michigan, United States

View Trial Details